Enerpac Tool Group Class A Earnings Calls
| Release date | Jun 25, 2026 |
| EPS estimate | $0.490 |
| EPS actual | - |
| Revenue estimate | 165.025M |
| Revenue actual | - |
| Expected change | +/- 2.76% |
| Release date | Mar 25, 2026 |
| EPS estimate | $0.390 |
| EPS actual | $0.390 |
| Revenue estimate | 149.777M |
| Revenue actual | 154.807M |
| Revenue Surprise | 3.36% |
| Release date | Dec 17, 2025 |
| EPS estimate | $0.370 |
| EPS actual | $0.360 |
| EPS Surprise | -2.70% |
| Revenue estimate | 145.933M |
| Revenue actual | 144.208M |
| Revenue Surprise | -1.18% |
| Release date | Oct 15, 2025 |
| EPS estimate | $0.507 |
| EPS actual | $0.520 |
| EPS Surprise | 2.56% |
| Revenue estimate | 164.033M |
| Revenue actual | 167.515M |
| Revenue Surprise | 2.12% |
Last 4 Quarters for Enerpac Tool Group Class A
Below you can see how EPAC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Oct 15, 2025 |
| Price on release | $40.31 |
| EPS estimate | $0.507 |
| EPS actual | $0.520 |
| EPS surprise | 2.56% |
| Date | Price |
|---|---|
| Oct 09, 2025 | $38.99 |
| Oct 10, 2025 | $38.64 |
| Oct 13, 2025 | $39.53 |
| Oct 14, 2025 | $40.31 |
| Oct 15, 2025 | $40.31 |
| Oct 16, 2025 | $42.24 |
| Oct 17, 2025 | $41.98 |
| Oct 20, 2025 | $41.91 |
| Oct 21, 2025 | $42.49 |
| 4 days before | 3.39% |
| 4 days after | 5.41% |
| On release day | 4.79% |
| Change in period | 8.98% |
| Release date | Dec 17, 2025 |
| Price on release | $39.26 |
| EPS estimate | $0.370 |
| EPS actual | $0.360 |
| EPS surprise | -2.70% |
| Date | Price |
|---|---|
| Dec 11, 2025 | $40.18 |
| Dec 12, 2025 | $40.55 |
| Dec 15, 2025 | $39.98 |
| Dec 16, 2025 | $39.40 |
| Dec 17, 2025 | $39.26 |
| Dec 18, 2025 | $35.81 |
| Dec 19, 2025 | $37.23 |
| Dec 22, 2025 | $38.59 |
| Dec 23, 2025 | $39.85 |
| 4 days before | -2.28% |
| 4 days after | 1.50% |
| On release day | -8.79% |
| Change in period | -0.81% |
| Release date | Mar 25, 2026 |
| Price on release | $37.48 |
| EPS estimate | $0.390 |
| EPS actual | $0.390 |
| Date | Price |
|---|---|
| Mar 19, 2026 | $36.25 |
| Mar 20, 2026 | $35.97 |
| Mar 23, 2026 | $36.75 |
| Mar 24, 2026 | $37.34 |
| Mar 25, 2026 | $37.48 |
| Mar 26, 2026 | $34.54 |
| Mar 27, 2026 | $34.34 |
| Mar 30, 2026 | $35.21 |
| Mar 31, 2026 | $36.47 |
| 4 days before | 3.39% |
| 4 days after | -2.69% |
| On release day | -7.84% |
| Change in period | 0.607% |
| Release date | Jun 25, 2026 |
| Price on release | - |
| EPS estimate | $0.490 |
| EPS actual | - |
| Date | Price |
|---|---|
| May 28, 2026 | $33.81 |
| May 29, 2026 | $33.49 |
| Jun 01, 2026 | $32.93 |
| Jun 02, 2026 | $33.16 |
| Jun 03, 2026 | $33.02 |
Enerpac Tool Group Class A Earnings Call Transcript Summary of Q1 2026
Enerpac reported Q1 FY2026 results largely in line with expectations. Industrial Tools & Services (IT&S) product sales grew ~4% organically and product orders accelerated across all regions, giving management increased confidence for the year. Services revenue declined—principally in the U.K.—and remains margin dilutive; management is consolidating and selectively repricing/reshaping the service footprint to target higher‑margin work. Gross profit margin was 50.7%, with adjusted EBITDA of $32.4M (22.4% margin) and adjusted EPS of $0.36. Tariff-driven cost pressure was largely offset dollar-for-dollar by pricing and productivity; management expects tariff pressure to ease in the second half. Inventory was increased (~15% higher) to meet stronger order rates. Balance sheet remains strong: net debt $49M (net debt / adjusted EBITDA 0.3) and total liquidity $539M. The company repurchased $15M of stock in the quarter and reiterated FY2026 guidance: organic revenue +1% to +4%, adjusted EBITDA growth ≈6% at the midpoint, free cash flow $100–$110M, and EPS $1.85–$2.0. Management is increasing investment in innovation (more product launches planned in FY2026), expanding commercial coverage (India, Australia, Philippines), upgrading e-commerce, and pursuing strategic M&A with an active deal funnel. Cortland (biomedical) continues to deliver strong, high‑margin growth. Overall message to investors: stable financial position, defensible margins, accelerating product order momentum, targeted investments to drive midterm growth, and disciplined M&A appetite.
Sign In
Buy EPAC